SCHEMBL7210396

SCHEMBL7210396

[CH2]S(=O)(=O)c1ccc(CCCC)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 5/20 0.67
SMN1; SMN2 Q16637 3/20 0.67
FFAR1 O14842 1/20 0.51
FFAR4 Q5NUL3 1/20 0.51
CA1 P00915 2/20 0.50
LMNA P02545 2/20 0.50
HTT P42858 2/20 0.50
CA12 O43570 1/20 0.50
CA9 Q16790 1/20 0.50
TSHR P16473 1/20 0.50
HPGD P15428 2/20 0.49
ALDH1A1 P00352 1/20 0.48
HSD17B10 Q99714 1/20 0.48
CNR2 P34972 1/20 0.48
THRA P10827 1/20 0.47
THRB P10828 1/20 0.47
AKT1 P31749 1/20 0.47
DRD2 P14416 1/20 0.46
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10791903 0.83 CA2 (0.71) CA2SMN1; SMN2FFAR1FFAR4CA1
SCHEMBL27366281 0.82 CA2 (0.69) CA2SMN1; SMN2FFAR1FFAR4CA1
SCHEMBL7216900 0.82 CA2 (0.69) CA2SMN1; SMN2FFAR1FFAR4CA1
SCHEMBL10179705 0.82 CA2 (0.69) CA2SMN1; SMN2FFAR1FFAR4CA1
SCHEMBL607623 0.80 CA2 (1.00) CA2SMN1; SMN2CA1LMNAHTT
SCHEMBL282318 0.80 CA2 (0.67) CA2SMN1; SMN2FFAR1FFAR4CA1
SCHEMBL269162 0.80 CA2 (0.67) CA2SMN1; SMN2FFAR1FFAR4CA1
SCHEMBL28503721 0.80 CA2 (0.67) CA2SMN1; SMN2FFAR1FFAR4CA1
SCHEMBL10181728 0.79 CA2 (0.61) CA2SMN1; SMN2FFAR1FFAR4CA1
SCHEMBL4686641 0.79 CA2 (0.61) CA2SMN1; SMN2FFAR1FFAR4CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030166687-A1 ALPHA-HYDROXY,-AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS PHARMACIA & UPJOHN COMPANY 2003-09-04 US disclosed
EP-1037868-B1 $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS UPJOHN CO (US) 2003-02-05 EP disclosed
US-6437177-B1 DISEASES INVOLVING CONNECTIVE TISSUE DEGRADATION; ARTHRITIS, OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, DERMAL, OR GASTRIC ULCERATION, AND ASTHMA; 2-HYDROXY-2-(PHENYLTHIO) METHYL-3-(4-BUTOXYBENZENESULFONYL)PROPIONIC ACID PHARMACIA & UPJOHN COMPANY 2002-08-20 US disclosed
EP-1037868-A2 $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS PHARMACIA & UPJOHN COMPANY (US) 2000-09-27 EP disclosed
WO-1999026909-A2 ALPHA-HYDROXY, -AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS PHARMACIA & UPJOHN COMPANY (US) 1999-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166687-A1 ALPHA-HYDROXY,-AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS MMP1, MMP8, HRH3 CA2 1634/4885SMN1; SMN2 3029/4885FFAR1 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.